Scholarlink

Background <p>Malaria remains a significant public health challenge in sub-Saharan Africa and Southeast Asia, with <i>Plasmodium falciparum</i> responsible for the majority of infections and deaths, particularly among children aged &lt; 5&#xa0;years. In Tanzania, the widespread use of antimalarial drugs, such as sulfadoxine-pyrimethamine for preventive therapy and artemisinin-based combination therapies as first-line treatment, has prompted concerns about the emergence and spread of drug resistance. The prolonged use of these drugs may have influenced resistance patterns, varying over time. Moreover, some <i>P. falciparum</i> samples have been reported as rapid diagnostic test (RDT)-negative despite microscopic confirmation of <i>P. falciparum</i> infection, raising questions about whether such false-negative results are due to poor-quality RDT kits or genetic deletions in the parasite.</p> Methods <p>This study investigated drug resistance dynamics and potential false-negative RDT results in <i>P. falciparum</i> by analyzing molecular markers in <i>pfdhps, pfdhfr</i>, <i>pfkelch13,</i> and <i>pfhrp2</i>/<i>3</i>, with the 18S rRNA gene used as a housekeeping control to verify DNA quality and confirm true parasite positivity.</p> Results <p>Molecular analysis revealed a decline in the triple <i>pfdhfr</i> mutation paired with double <i>pfdhps</i> mutations, alongside an increase in mixed <i>dhfr–dhps</i> haplotypes (<i>χ</i><sup>2</sup> = 28.94, <i>p</i> &lt; 0.001), indicating ongoing genetic diversification under drug pressure. Wild-type parasites were predominant (56–76%), and most <i>pfkelch13</i> mutations were located in the non-propeller region, with no validated or candidate mutations associated with artemisinin-resistance detected. <i>P. falciparum</i>-infected samples that were RDT-negative showed a high frequency of both complete and partial deletions in <i>pfhrp2</i> and <i>pfhrp3</i>, potentially explaining RDT inconsistencies and false-negative results.</p> Conclusions <p><i>P. falciparum</i> remains the dominant species in this high-transmission region, showing a persistently high rate of antifolate resistance. Significant associations between triple <i>pfdhfr</i> and double <i>pfdhps</i> resistance markers were observed between 2021 and 2024. The continued susceptibility to artemisinin emphasizes the need for ongoing molecular surveillance and monitoring of <i>hrp2/hrp3</i> deletions to support malaria control strategies in Tanzania.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular characterization of antimalarial resistance and hrp2/3 deletions in Plasmodium falciparum strains from Mtwara, Tanzania (2021–2024)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月28日

查看全文
  • Piyathida Thapradit,
  • Watcharee Pagornrat,
  • Wanassanan Madmanee,
  • Raweewan Sangsri,
  • Kiattawee Choowongkomon,
  • Salum Mshamu,
  • Deus S. Ishengoma,
  • Arjen M. Dondorp,
  • Lorenz Von Seidlein,
  • Mallika Imwong

摘要

Background

Malaria remains a significant public health challenge in sub-Saharan Africa and Southeast Asia, with Plasmodium falciparum responsible for the majority of infections and deaths, particularly among children aged < 5 years. In Tanzania, the widespread use of antimalarial drugs, such as sulfadoxine-pyrimethamine for preventive therapy and artemisinin-based combination therapies as first-line treatment, has prompted concerns about the emergence and spread of drug resistance. The prolonged use of these drugs may have influenced resistance patterns, varying over time. Moreover, some P. falciparum samples have been reported as rapid diagnostic test (RDT)-negative despite microscopic confirmation of P. falciparum infection, raising questions about whether such false-negative results are due to poor-quality RDT kits or genetic deletions in the parasite.

Methods

This study investigated drug resistance dynamics and potential false-negative RDT results in P. falciparum by analyzing molecular markers in pfdhps, pfdhfr, pfkelch13, and pfhrp2/3, with the 18S rRNA gene used as a housekeeping control to verify DNA quality and confirm true parasite positivity.

Results

Molecular analysis revealed a decline in the triple pfdhfr mutation paired with double pfdhps mutations, alongside an increase in mixed dhfr–dhps haplotypes (χ2 = 28.94, p < 0.001), indicating ongoing genetic diversification under drug pressure. Wild-type parasites were predominant (56–76%), and most pfkelch13 mutations were located in the non-propeller region, with no validated or candidate mutations associated with artemisinin-resistance detected. P. falciparum-infected samples that were RDT-negative showed a high frequency of both complete and partial deletions in pfhrp2 and pfhrp3, potentially explaining RDT inconsistencies and false-negative results.

Conclusions

P. falciparum remains the dominant species in this high-transmission region, showing a persistently high rate of antifolate resistance. Significant associations between triple pfdhfr and double pfdhps resistance markers were observed between 2021 and 2024. The continued susceptibility to artemisinin emphasizes the need for ongoing molecular surveillance and monitoring of hrp2/hrp3 deletions to support malaria control strategies in Tanzania.